Sermorelin Research for Anti-Aging
An evidence-based overview of research examining Sermorelin in the context of anti-aging. This page synthesizes findings from peer-reviewed literature.
Research Summary
Sermorelin has been extensively studied for age-related GH decline (somatopause). NIH research demonstrated that GHRH(1-29) reversed age-related decreases in GH and IGF-1 levels in elderly men, suggesting potential for addressing age-related hormonal changes.
A 6-month randomized trial in healthy older adults (65-88 years) showed GHRH increased IGF-1 and lean mass while decreasing fat mass, without major adverse effects. These findings support the concept of GHRH therapy for age-related body composition changes.
The Italian research groups at Turin and Milan have contributed significantly to understanding GHRH in somatopause, demonstrating that age-related GH decline is hypothalamic (not pituitary) in origin, making GHRH an appropriate intervention target.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Anti-Aging
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Sermorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.